Clinical Trial Update: Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating iruplinalkib tablets as postoperative adjuvant therapy for Stage IA ALK-positive non-small cell lung cancer with high-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iruplinalkib (iruplinalkib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING